Clinical and Metabolic Effects of Medroxyprogesterone Acetate and Ethinyl Estradiol Plus Drospirenone in Women with Polycystic Ovary Syndrome

    Suna Özdemir, Hüseyin Görkemli, Kazım Gezginç, Mustafa Özdemir, Aysel Kıyıcı
    TLDR MPA improved hormonal imbalances and acne in women with PCOS without affecting metabolism.
    The study investigated the effects of medroxyprogesterone acetate (MPA) and ethinyl estradiol plus drospirenone on women with polycystic ovary syndrome (PCOS). Sixty-three women participated, with results showing that MPA treatment led to significant decreases in serum luteinizing hormone, total testosterone, free androgen index, acne, and seborrhea scores, without affecting lipid or carbohydrate metabolism. In contrast, the ethinyl estradiol plus drospirenone group experienced increases in lipid and hormone values, while acne, seborrhea, hair loss, and Ferriman-Gallwey scores decreased. Both treatments provided good menstrual cycle control, but only MPA showed beneficial hormonal changes without metabolic impact.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results

    Related Research

    5 / 5 results